不明来源栓塞性卒中后复发性缺血性卒中的特征:随机临床试验二次分析
该研究基于NAVIGATE-ESUS试验(n=7213)的二次分析,对309例复发性缺血性卒中患者进行病因分型,发现58%复发仍为ESUS,42%为非ESUS,其中心源性栓塞占32%;心房颤动相关的复发卒中致残率和死亡率更高,且不同治疗组间复发风险无显著差异。
要点
- ESUS后复发卒中多数仍为ESUS,心源性栓塞占少数但致残致死率高。
- 复发卒中的梗死部位左侧半球更常见,与首发卒中存在一致性。
- 利伐沙班与阿司匹林组间各亚型复发风险无显著差异。
核心结论
- ESUS后大多数复发性卒中为栓塞性且来源不明,心房颤动相关复发虽少但更常致残和致命。
研究设计与样本
- NAVIGATE-ESUS随机临床试验的二次事后分析,纳入7213例近期ESUS患者,其中309例经盲法判定为复发性缺血性卒中。
主要发现
- 中位随访11个月期间年化复发率为4.6%,309例复发卒中中39例(13%)因检查不足无法分类。
- 270例可分类复发卒中中,156例(58%)为ESUS,114例(42%)为非ESUS(其中心源性栓塞37例[32%],动脉粥样硬化性26例[23%],腔隙性35例[31%],其他明确病因16例[14%])。
- 27例(9%)复发缺血性卒中患者发现心房颤动,与其他病因相比,其改良Rankin量表评分中位变化更高(2[IQR,3] vs 0[IQR,1]),死亡率更高(15% vs 1%)。
- 各治疗组间复发风险按亚型无显著差异。
- 首发和复发卒中的梗死部位均更多位于左侧半球(分别为46%和54%),而非右侧半球(40%和37%)或脑干/小脑(14%和9%)。
关键数值与推荐
- 复发性缺血性卒中定义为经盲法判定为缺血性卒中,排除无神经影像或尸检无法确定缺血或出血的5例。
- 病因分类由当地研究者分为ESUS或非ESUS(心源性栓塞、动脉粥样硬化性、腔隙性、其他明确病因或检查不足)。
- 心房颤动相关复发卒中:改良Rankin量表评分中位变化2(IQR,3)vs 0(IQR,1),死亡率15% vs 1%。
临床怎么用
- ESUS后复发卒中多数仍为ESUS,需更广泛检查以明确栓塞来源并优化抗栓策略。
- 心房颤动相关复发卒中虽少但致残致死率高,应重视心房颤动的筛查。
局限性
- 本研究为二次事后分析,可能存在选择偏倚和残余混杂。
- 部分复发卒中因诊断检查不足无法进行病因分类(13%)。
- 当地研究者分类可能受限于检查不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The concept of embolic stroke of undetermined source (ESUS) unifies a subgroup of cryptogenic strokes based on neuroimaging, a defined minimum set of diagnostic tests, and exclusion of certain causes. Despite an annual stroke recurrence rate of 5%, little is known about the etiology underlying recurrent stroke after ESUS. OBJECTIVE: To identify the stroke subtype of recurrent ischemic strokes after ESUS, to explore the interaction with treatment assignment in each category, and to examine the consistency of cerebral location of qualifying ESUS and recurrent ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: The NAVIGATE-ESUS trial was a randomized clinical trial conducted from December 23, 2014, to October 5, 2017. The trial compared the efficacy and safety of rivaroxaban and aspirin in patients with recent ESUS (n = 7213). Ischemic stroke was validated in 309 of the 7213 patients by adjudicators blinded to treatment assignment and classified by local investigators into the categories ESUS or non-ESUS (ie, cardioembolic, atherosclerotic, lacunar, other determined cause, or insufficient testing). Five patients with recurrent strokes that could not be defined as ischemic or hemorrhagic in absence of neuroimaging or autopsy were excluded. Data for this secondary post hoc analysis were analyzed from March to June 2019. INTERVENTIONS: Patients were randomly assigned to receive rivaroxaban, 15 mg/d, or aspirin, 100 mg/d. MAIN OUTCOMES AND MEASURES: Association of recurrent ESUS with stroke characteristics. RESULTS: A total of 309 patients (205 men [66%]; mean [SD] age, 68 [10] years) had ischemic stroke identified during the median follow-up of 11 (interquartile range [IQR], 12) months (annualized rate, 4.6%). Diagnostic testing was insufficient for etiological classification in 39 patients (13%). Of 270 classifiable ischemic strokes, 156 (58%) were ESUS and 114 (42%) were non-ESUS (37 [32%] cardioembolic, 26 [23%] atherosclerotic, 35 [31%] lacunar, and 16 [14%] other determined cause). Atrial fibrillation was found in 27 patients (9%) with recurrent ischemic stroke and was associated with higher morbidity (median change in modified Rankin scale score 2 [IQR, 3] vs 0 (IQR, 1]) and mortality (15% vs 1%) than other causes. Risk of recurrence did not differ significantly by subtype between treatment groups. For both the qualifying and recurrent strokes, location of infarct was more often in the left (46% and 54%, respectively) than right hemisphere (40% and 37%, respectively) or brainstem or cerebellum (14% and 9%, respectively). CONCLUSIONS AND RELEVANCE: In this secondary analysis of randomized clinical trial data, most recurrent strokes after ESUS were embolic and of undetermined source. Recurrences associated with atrial fibrillation were a minority but were more often disabling and fatal. More extensive investigation to identify the embolic source is important toward an effective antithrombotic strategy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02313909.
引用
- Veltkamp R, Pearce LA, Korompoki E, et al. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 32628266. doi:10.1001/jamaneurol.2020.1995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。